PMC:7127386 / 239-453
Annnotations
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 27 | 97-108 | Species | denotes | coronavirus | Tax:11118 |
| 28 | 194-204 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
| 29 | 205-213 | Species | denotes | patients | Tax:9606 |
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T3 | 194-202 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T3 | 26-35 | Chemical | denotes | antiviral | http://purl.obolibrary.org/obo/CHEBI_22587 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T4 | 0-214 | Sentence | denotes | We evaluated the in vitro antiviral effect of compounds that were previously reported to inhibit coronavirus replication and compounds that are currently under evaluation in clinical trials for SARS-CoV-2 patients. |
LitCovid-PMC-OGER-BB
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T8 | 46-55 | CHEBI:36357;CHEBI:36357 | denotes | compounds |
| T9 | 97-108 | NCBITaxon:11118 | denotes | coronavirus |
| T10 | 109-120 | GO:0006260 | denotes | replication |
| T11 | 125-134 | CHEBI:36357;CHEBI:36357 | denotes | compounds |
| T12 | 194-204 | SP_7 | denotes | SARS-CoV-2 |
| T24338 | 46-55 | CHEBI:36357;CHEBI:36357 | denotes | compounds |
| T2435 | 97-108 | NCBITaxon:11118 | denotes | coronavirus |
| T41112 | 109-120 | GO:0006260 | denotes | replication |
| T93186 | 125-134 | CHEBI:36357;CHEBI:36357 | denotes | compounds |
| T5199 | 194-204 | SP_7 | denotes | SARS-CoV-2 |